NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Wild weather has seen the Sydney Smash fizzle without a whimper as the Sydney Sixers shared the points with cross-town rivals the Sydney Thunder in a washout at the SCG. Watch every game of the ...
Get the Real Story Behind Every Major Earnings Report In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback